Clinical trial · Observational
Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium
REtrospective, obserVational Study to Describe the Treatment Patterns and Outcomes of Epidermal Growth Factor Receptor Mutant (EGFRm) Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Patients in Belgium
NCT03761901CI-TRIAL-00045012REVEALcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a retrospective, observational, multicentre study to evaluate treatment patterns and outcomes of patients diagnosed with locally advanced or metastatic EGFRm NSCLC in Belgium
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Non-Small-Cell Lung | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 1L treatment | Drug | — | UNRESOLVED |
| 2L Treatment | Drug | — | UNRESOLVED |
| 3L treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients with EGFR mutation positive NSCLC
- interventionNames
- Drug: 1L treatment
- Drug: 2L Treatment
- Drug: 3L treatment
Primary outcomes (9)
- measure
- demographic characteristics of patients diagnosed between 1 September 2015 and 31 December 2017
- timeFrame
- 28 months
- measure
- NSCLC characteristics at diagnosis between 1 september 2015 and 31 December 2017
- timeFrame
- 28 months
- measure
- NSCLC disease characteristics at start of 2L or 3L treatment during observation window
- timeFrame
- 36 months
- description
- observation window: between date of diagnosis until the data cut-off , 01 September 2018, end of clinical activity or death, whichever comes first. Descriptive statitistics will be used to analyse these endpoints.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Male or female, aged at least 18 years * Pathologically confirmed NSCLC * Tumour harbours a mutation of EGFR * Diagnosis (radiologically or pathologically confirmed) of locally advanced or metastatic NSCLC, not amenable to curative surgery or chemoradiotherapy between 01 September 2015 and 31 December 2017 Exclusion Criteria: * No follow-up data available after diagnosis of locally advanced or metastatic EGFRm NSCLC * Patients who objected to participation to the study
References
Publications (1)
- DERIVEDCuppens K, Lodewyckx L, Demedts I, Decoster L, Colinet B, Deschepper K, Janssens A, Galdermans D, Pieters T; REVEAL Study Group. Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study. Drugs Real World Outcomes. 2021 Jun;8(2):141-152. doi: 10.1007/s40801-021-00243-w. Epub 2021 Mar 12. PMID 33710523